Due diligence findings and how they change the price: cost and likely outcome depends on how directly a finding maps to quantifiable loss, what the disclosure schedule already covers and how much room remains to negotiate before signing. A finding rarely produces an automatic discount; it produces a negotiating position, priced against materiality thresholds, baskets and whatever liability cap the agreement carries.
Who this concerns
This question comes up in every share purchase or asset deal where due diligence has already started: private equity buyers reviewing a Swedish target, trade buyers acquiring a competitor or supplier, and sellers preparing a data room who want to anticipate what will come back at them once the buyer's team has gone through it. It also concerns the finance and legal function inside the target itself, because the findings that actually move price are rarely the ones anyone flagged in advance. An unbooked tax liability, a supply contract that terminates on change of control, a software assignment that was never formally signed, or a customer complaint that never reached the accounts department all fall into this category.
The contracts and transactions practice sees this pattern most often in mid-market deals, where the buyer's team has limited time between signing and closing and the seller has limited appetite to reopen commercial terms already agreed in principle. The real question is rarely whether a finding is genuine. It is whether it is material enough, provable enough and disclosed clearly enough to justify moving the number, and whether the transaction documents give either side a contractual route to act on it.
What the law says
Swedish law does not prescribe a formula for adjusting a purchase price after a due diligence finding surfaces. There is no statutory price-correction mechanism comparable to a consumer remedy. The entire mechanism is contractual, built into the share purchase agreement through representations, warranties, indemnities and the disclosure letter that qualifies them. Under Swedish law as it currently stands, the default position on a share deal is that the buyer takes the company as it stands on completion, subject only to what the seller has actually warranted and what has been specifically indemnified.
That makes the drafting stage decisive, not the discovery stage. A warranty catalogue, referred to in Swedish practice as a garantikatalog, sets out the representations the seller gives about the target's accounts, contracts, tax position, employees and assets. It defines what counts as a breach in the first place. A finding that falls outside every warranty and every indemnity has no contractual hook, however serious it looks commercially. Conversely, a finding that squarely breaches a warranty gives the buyer a claim under the agreement itself, independent of whether either side still wants the deal to proceed on the original terms.
General principles of good faith and pre-contractual disclosure can, in narrow cases, support a claim where a seller actively concealed something material during negotiations rather than simply failing to disclose it. That route exists, but it is slower and harder to prove than a warranty claim already built into the transaction documents. It is not a substitute for getting the warranty catalogue and the disclosure letter right before signature.
How it works in practice
How a finding turns into a number
The first step is establishing whether the finding represents a one-off cost, a recurring reduction in earnings, or a contingent liability that may never crystallise. A one-off cost, such as an unpaid invoice or a fine already assessed, is usually deducted once from the price. A finding that reduces recurring profit is treated differently: buyers commonly apply the same multiple used to price the whole company, on the basis that a permanent reduction in EBITDA reduces enterprise value by more than the raw figure suggests. Contingent liabilities sit in between and are often addressed through an indemnity rather than a price cut, precisely because their size is not yet known.
Materiality and disclosure qualifiers
Swedish SPA drafting typically distinguishes between general disclosure, meaning everything in the data room, and specific disclosure, meaning items expressly called out against a particular warranty. A finding that was fairly and specifically disclosed usually cannot support a claim later, because the warranty is treated as qualified by that disclosure from the outset. Whether disclosure was fair enough to qualify a warranty is one of the most heavily contested points once a claim is raised, and it is decided by looking at how the item was presented, not by whether anyone on the buy side actually opened the file.
Baskets, caps and de minimis thresholds
Most agreements set a de minimis threshold below which a finding does not count at all, a basket that has to be filled before any claim becomes payable, and a cap that limits total exposure regardless of how many findings there are. None of these figures is fixed by law or by uniform market practice; each is negotiated for the specific transaction, usually in proportion to enterprise value and to how much of the price is deferred. A finding that would otherwise justify a meaningful adjustment can still produce nothing if the basket was never breached.
Escrow and price holdback as an alternative to a discount
Where a finding is real but its final value cannot be confirmed before closing, parties frequently agree to hold back part of the price in escrow rather than negotiate an immediate reduction. This defers the argument about quantum without blocking completion, and it shifts the practical question from "how much should the price fall" to "what has to happen before the escrow is released".
Renegotiating versus walking away
Leverage before signing is fundamentally different from leverage after signing. Before signing, a serious finding can justify walking away entirely, because no binding obligation exists yet. After signing but before closing, the buyer's options are usually limited to whatever conditions and price-adjustment mechanisms were built into the agreement itself; a unilateral refusal to close on the basis of a finding not covered by those mechanisms is a high-risk move that can expose the buyer to a claim for breach.
Findings that cross into other regimes
Some findings are not warranty issues at all. A target's activities may trigger a filing obligation that overlaps with the transaction's own merger control and investment screening review, in which case the exposure is regulatory rather than contractual and cannot be cured by adjusting the price. Software and IP findings raise a related problem: if commissioned code was never properly assigned to the target, the question is one of ownership, not valuation, and is better addressed through the mechanics set out in our guide to copyright in commissioned software before it is priced at all. Construction-heavy targets bring their own category of finding, typically unresolved ÄTA-arbeten, the Swedish term for variation and additional works instructed but not formally agreed under the underlying contract. Whether that exposure sits with the buyer or the seller after completion depends on how the underlying works were procured, which is covered in detail in our explanation of construction contracts under AB 04 and ABT 06.
Cross-border deals and foreign parties
Where the buyer, the seller or the target's parent sits outside Sweden, the analysis above still applies to the Swedish target, but two further layers are added. First, the governing law and forum clause in the SPA determines whether a Swedish warranty claim can even be brought where the parties expect, and enforcement against a foreign counterparty is a separate question from the merits of the claim itself. Second, a finding involving a foreign subsidiary or foreign-sourced contract may need to be assessed under that jurisdiction's law before it can be quantified for Swedish price-adjustment purposes, particularly for tax and employment findings, which rarely travel across borders on the same terms.
What to check before treating a finding as a price issue
- Whether the finding falls within an existing warranty, an indemnity, or neither.
- Whether it was disclosed, and if so, how specifically.
- Whether it has already been reflected in the price through a working capital adjustment or an earlier change in the multiple.
- Whether it is a one-off cost, a recurring earnings effect, or a contingent liability, since each is priced differently.
- Whether the basket, cap and time limits in the draft agreement still leave room for a claim of this size.
- Whether the finding triggers a separate regulatory filing that exists independently of the price.
The numbers
There is no legally fixed percentage or formula that converts a due diligence finding into a price adjustment. The order of magnitude depends entirely on the transaction: whether the finding reduces recurring profit or represents a one-off cost, whether it is tax deductible, and what multiple was used to price the company in the first place. A recurring earnings reduction is commonly treated as more expensive than its face value, because it is run through the same multiple applied to the rest of the business.
The basket, the cap on liability and the de minimis threshold are all figures the parties set for that specific deal; none of them is imposed by statute or follows a uniform market convention. What stays consistent across transactions is the sequence in which they operate. A finding first has to clear the de minimis threshold to count at all, then contribute toward filling the basket before any claim becomes payable, and finally sit within the overall liability cap that limits total exposure across every claim combined. A finding that would otherwise justify a significant adjustment can still produce nothing in practice if the basket it needs to fill was never breached, or if the claim window closed before it was raised.
Where it usually goes wrong
A finding discovered after closing, once the relevant warranty or indemnity has already expired, generally has no contractual home left. If survival periods were not drafted to cover the type of issue that later surfaces, the buyer is left arguing general contract principles, which is a far weaker position than a warranty claim with a built-in remedy.
Fair disclosure is the second recurring failure point on the buyer's side. A finding sitting in a data room annex that was properly and specifically flagged usually cannot support a claim later, regardless of whether anyone reviewed it carefully at the time. The test applied is whether the disclosure was fair and specific enough to qualify the relevant warranty, not whether the buyer's team actually read it.
Double counting is the recurring failure on both sides. If a finding was already reflected in the price through a working capital true-up or an earlier reduction in the agreed multiple, running the same figure through a warranty claim after closing typically fails, because the loss has effectively already been priced once.
Findings tied to matters that also fall under merger control or investment screening obligations sit outside ordinary price-adjustment mechanics entirely. A missed filing obligation identified during due diligence is a regulatory exposure that a price adjustment in the SPA cannot cure, however the number is set.
What to do next
Working out whether a specific finding changes the price, and by how much, means reading the warranty catalogue, the disclosure letter and the basket and cap mechanics against the actual finding, not treating any of them as a template. That is the point at which self-directed review usually stops being sufficient and a proper assessment of the position, and of what is realistically recoverable, becomes necessary.
Where the finding relates to software licensing or a SaaS arrangement inside the target, our step-by-step guide to IT and SaaS agreements for a Swedish customer covers the specific clauses that tend to generate this category of finding. For everything else, the practical next step is an assessment call to look at the actual documents: get in touch to arrange one.
Does a due diligence finding automatically reduce the purchase price?
No. A finding only affects the price if it falls within a warranty or indemnity that survives to the relevant date, has not already been priced through disclosure or an earlier adjustment, and clears the basket and de minimis thresholds set in the agreement. Outside those mechanics, a finding may still be commercially significant without giving either side a contractual route to adjust the number.
What happens if a finding surfaces after signing but before closing?
The buyer's options depend on what conditions and remedies the signed agreement already contains. Some agreements allow a price adjustment or a right to walk away for findings above a stated threshold discovered in this window; others leave the buyer with only a post-closing claim once the deal completes. Reading this mechanism before relying on it is essential, because assuming a remedy exists that was never drafted is a common and costly mistake.
Can a seller refuse to adjust the price for a disclosed finding?
Generally yes, if the disclosure was specific enough to qualify the relevant warranty. A seller who disclosed an item fairly and specifically is usually entitled to treat the price as reflecting that disclosure already, meaning the buyer's remedy, if one exists, sits elsewhere in the agreement rather than in a further price reduction for the same item.